Moderna, Inc


SKU: MRNA Category:


Moderna, Inc: Initiation Of Coverage – Product Pipeline, Commercial Portfolio & 5 Key Drivers!


This is our first report on Moderna, Inc., a renowned biotechnology company utilizing mRNA technology in the development of therapeutics and vaccines. The company entered 2024 optimistic despite challenging 2023 results. The company’s revenue for 2023 stood at $6.1 billion, with a net loss of $4.7 billion. However, these results encompass primarily noncash charges of $3.7 billion related to the resizing of manufacturing and the tax valuation allowance. Excluding these elements, the net loss is reduced to $1.6 billion.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!